Trial Profile
Evaluation of [18F]FluciclatidePositron Emission Tomography For the Prediction of Response to Pazopanib In Patients With Metastatic Renal Cell Carcinoma: An Exploratory Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2016
Price :
$35
*
At a glance
- Drugs Fluciclatide F-18 (Primary)
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 27 Feb 2016 Status changed from recruiting to discontinued as per Clinicaltrials.gov record.
- 02 May 2014 New trial record